Ironwood Pharmaceuticals, Inc. (IRWD) Given New $22.00 Price Target at Mizuho

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) had its target price upped by Mizuho from $21.00 to $22.00 in a research report report published on Tuesday, July 4th, StockTargetPrices.com reports. They currently have a buy rating on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. Cowen and Company set a $20.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, April 13th. BTIG Research reiterated a buy rating and issued a $21.00 price target (up from $18.00) on shares of Ironwood Pharmaceuticals in a research note on Monday, March 13th. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, June 23rd. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, June 2nd. Finally, Wedbush reaffirmed a neutral rating and set a $13.00 price target on shares of Ironwood Pharmaceuticals in a report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. Ironwood Pharmaceuticals presently has an average rating of Hold and a consensus target price of $17.89.

Ironwood Pharmaceuticals (NASDAQ IRWD) traded up 5.71% on Tuesday, reaching $17.60. 1,750,832 shares of the company’s stock were exchanged. The company’s market cap is $2.62 billion. Ironwood Pharmaceuticals has a 52-week low of $12.48 and a 52-week high of $19.94. The firm’s 50 day moving average price is $18.36 and its 200 day moving average price is $17.09.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.14. Ironwood Pharmaceuticals had a negative return on equity of 195.06% and a negative net margin of 46.49%. The company had revenue of $52.16 million during the quarter, compared to the consensus estimate of $69.39 million. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. The business’s revenue was down 21.0% compared to the same quarter last year. On average, analysts expect that Ironwood Pharmaceuticals will post ($0.91) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Ironwood Pharmaceuticals, Inc. (IRWD) Given New $22.00 Price Target at Mizuho” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/07/30/ironwood-pharmaceuticals-inc-irwd-price-target-raised-to-22-00-at-mizuho-updated-updated-updated.html.

In related news, insider Thomas A. Mccourt sold 30,000 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $18.20, for a total value of $546,000.00. Following the completion of the sale, the insider now directly owns 30,000 shares of the company’s stock, valued at $546,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Halley E. Gilbert sold 35,000 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the sale, the insider now directly owns 35,000 shares of the company’s stock, valued at $691,250. The disclosure for this sale can be found here. Insiders own 7.63% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in IRWD. Principal Financial Group Inc. raised its stake in Ironwood Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 24,051 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 62 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in Ironwood Pharmaceuticals by 8.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 898 shares during the last quarter. Aperio Group LLC raised its stake in Ironwood Pharmaceuticals by 11.9% in the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 1,410 shares during the last quarter. Teachers Advisors LLC raised its stake in Ironwood Pharmaceuticals by 0.8% in the fourth quarter. Teachers Advisors LLC now owns 225,596 shares of the biotechnology company’s stock valued at $3,449,000 after buying an additional 1,859 shares during the last quarter. Finally, Swiss National Bank raised its stake in Ironwood Pharmaceuticals by 1.2% in the first quarter. Swiss National Bank now owns 205,300 shares of the biotechnology company’s stock valued at $3,502,000 after buying an additional 2,400 shares during the last quarter. 98.16% of the stock is owned by institutional investors.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Stock Target Prices

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply